Filing summary
Entity discrepancy: The supplied filing is Owens & Minor, Inc.’s Form 10-Q, not an Accendra Health Inc. filing. It covers the quarter ended March 31, 2013; the financial statements are unaudited. Verify the issuer before relying on this summary.
Business context and reporting period
Owens & Minor distributes medical and surgical supplies and provides healthcare logistics services. It reports Domestic and International segments. The International segment reflects the Movianto third-party logistics business acquired in August 2012, so year-over-year results include a new business absent from the 2012 comparison.
Financial performance
| Metric | Q1 2013 | Q1 2012 | Change |
|---|---|---|---|
| Net revenue | $2,275.7 million | $2,217.9 million | +2.6% |
| Gross margin | $279.1 million; 12.26% | $214.3 million; 9.66% | + $64.7 million |
| Operating earnings, GAAP | $47.9 million | $51.9 million | −7.7% |
| Adjusted operating earnings, non-GAAP | $49.9 million; 2.19% of revenue | $51.9 million; 2.34% | −$2.0 million |
| Net income | $26.1 million | $29.4 million | −11.1% |
| Diluted EPS | $0.41 | $0.46 | −$0.05 |
| Operating cash flow | $154.6 million | $101.9 million | +$52.7 million |
Adjusted net income was $27.6 million and adjusted diluted EPS was $0.44, excluding $2.0 million of acquisition-related and exit and realignment charges ($1.5 million after tax, or $0.03 per diluted share). These are non-GAAP measures.
Domestic revenue was $2,154.7 million and International revenue was $121.0 million; International reported a $3.0 million operating loss. Domestic operating earnings were $52.9 million, versus $51.9 million in the prior-year quarter. International revenue and earnings have no comparable Q1 2012 segment baseline in this filing.
Balance sheet, liquidity and capital
- At March 31, 2013, cash was $218.6 million, up from $97.9 million at year-end 2012. Current assets were $1,748.3 million and current liabilities $1,036.9 million.
- Long-term debt, excluding current portion, was $214.2 million. The company had $200 million of senior notes outstanding, maturing in 2016 at 6.35%, and no revolving-credit borrowings. The $350 million revolver had $345 million available after letters of credit; the company reported compliance with debt covenants.
- Operating cash flow increased substantially, primarily because accounts payable rose with payment timing. Investing used $14.7 million, including capital expenditures of approximately $14.8 million; financing used $17.4 million, including $15.2 million in dividends and $2.3 million in share repurchases.
- Quarterly dividend was $0.24 per share, up from $0.22. The company said it anticipated continuing quarterly dividends, subject to Board discretion and business conditions. The repurchase authorization had $16.6 million remaining and was scheduled to expire in February 2014.
Material changes, outlook and risks
- Revenue growth was driven primarily by Movianto. Domestic revenue declined 1.3% per sales day, which management said was a slower decline than in Q4 2012; it cited customer rationalization, lower hospital utilization and reduced government purchases.
- Movianto contributed to higher gross margin dollars and percentage, but also increased SG&A and depreciation. Management said Domestic gross margin benefited from supplier price changes and expected some benefit to be offset in later 2013 quarters. International gross margin was approximately 50% and may vary with seasonality and business mix.
- Management expected approximately $3.1 million of additional 2013 exit and realignment charges for Domestic activities initiated through March 31. Q1 recorded $2.0 million in acquisition-related and exit and realignment charges.
- No specific full-year revenue, earnings or EPS guidance is provided in the supplied filing text. Management believed cash and available financing would meet foreseeable needs, while noting exposure to economic conditions, customer and supplier credit, borrowing costs and access to financing.
- Other risks include pricing and competitive pressure, customer and supplier concentration, Movianto integration and international operations, healthcare regulation, information-system disruption or security breaches, fuel prices, foreign exchange, litigation and tax matters. A 1-day increase in consolidated DSO could tie up approximately $25 million of cash. The company estimated that each 10-cent-per-gallon diesel benchmark increase would reduce Domestic operating earnings by about $0.4 million annualized; a fixed-price agreement covered about one-third of anticipated 2013 Domestic fuel use.
Contingencies and unusual items
- Contractual customer performance obligations totaled $3.5 million, but none were accrued because management did not consider payment probable. Related deferred revenue was $1.0 million.
- A California review could result in contingent incentive payments of up to $7.0 million for prior periods; the amount and timing were uncertain.
- Currency translation generated a $7.8 million other comprehensive loss in Q1, contributing to total other comprehensive loss of $7.6 million. This reduced accumulated other comprehensive equity.
- The effective tax rate rose to 41.6% from 39.4%, largely due to foreign taxes. The filing reported no material legal-proceeding developments or changes to previously disclosed risk factors.
Key facts for investors to verify
- Confirm the issuer: the provided document identifies Owens & Minor, Inc., not Accendra Health Inc.
- Assess the contribution and integration costs of Movianto, including its International operating loss and year-over-year comparability effects.
- Reconcile the sharp gross-margin improvement with higher SG&A and lower operating earnings; distinguish GAAP results from management’s non-GAAP adjusted measures.
- Evaluate whether operating cash flow is sustainable given the filing’s attribution of much of the year-over-year increase to payment timing and higher accounts payable.
- Monitor Domestic sales trends, supplier-price offsets, planned restructuring charges, customer performance obligations and the unresolved California incentive review.
- Review debt-covenant headroom, revolver access, foreign-held cash and the sustainability of dividends and repurchases alongside capital spending needs.